-+ 0.00%
-+ 0.00%
-+ 0.00%

Adagene receives USD 2 million Exelixis milestone payment for SAFEbody ADC program

PUBT·09/09/2026 12:03:34
Listen to the news
Adagene receives USD 2 million Exelixis milestone payment for SAFEbody ADC program
  • Adagene reported a USD 2 million milestone payment from Exelixis tied to a preclinical milestone for SAFEbody ADC candidate XB404.
  • Exelixis also triggered an additional payment by selecting candidates for another SAFEbody antibody-drug conjugate program.
  • Adagene remains eligible for further development, commercialization milestones, and royalties on net sales under the collaboration.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090800PRIMZONEFULLFEED9822387) on September 09, 2026, and is solely responsible for the information contained therein.